Receptor News and Research

RSS

Researchers develop novel strategy to selectively target tumor microenvironments

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to improve therapeutic efficacy, with promising results.

25 Jun 2026

New review highlights TREM-1 receptor as target for inflammatory diseases

A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.

25 Jun 2026

Chronic stress helps tumors evade immune attack through gut microbes

Chronic psychological stress can help tumors evade immune attack through a chain of molecular events involving gut bacteria and viruses within those bacteria, according to a study led by Weill Cornell Medicine investigators.

25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026

New oral drug shows promise for chronic heart failure treatment

An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic heart failure.

24 Jun 2026

England faces widening obesity inequalities across regions and communities

This study is the first to analyse obesity trends from 2019 to 2025, using NHS England electronic health records covering nearly 55 million adults.

24 Jun 2026

Duke researchers discover molecules that target vital cell signaling proteins

To function normally, nearly every cell in the human body relies on G-protein coupled receptors (GPCRs) to receive and send signals. That's why GPCRs are targeted by roughly one-third of all FDA‑approved drugs.

24 Jun 2026

Natural microbial compound helps protect the gut from chronic inflammation

University of Louisville researchers have discovered how a naturally occurring microbial compound may help protect the gut and support future treatment strategies for inflammatory bowel disease (IBD).

24 Jun 2026

Microbes trigger cell death to boost cancer immunotherapy effectiveness

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, and immune-related adverse events.

24 Jun 2026

Researchers uncover key mechanism driving chronic Sjögren disease

Sjögren disease, an autoimmune disease characterized by dry mouth and dry eyes, may reduce patients’ quality of life.

24 Jun 2026

Eating 90 g of wholegrains daily linked to lower breast cancer risk

Research indicates that long-term wholegrain intake per Nordic guidelines is associated with reduced breast cancer risk, emphasizing food type differences.

24 Jun 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026